BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Leucovorin 50 mg/5 mL 200 mg/20 mL 1000 mg/100 mL (GMP) (F)(PFL) no preservative[1]	N/A	10 mg/mL[1]	50 mg: discard unused portion[1,2] 200 mg,1000 mg: 8 h F[1,2]	syringe	8 h RT[1,2]	
				0.05-10 mg/mL NS, D5W, Ringer's, LR, D10W, D5-NS[1,2] 50-250 mL†	**NS**, D5W, LR, Ringer's: 24 h RT[1] D10W, D5-NS: 8 h RT[1]	
Leucovorin 50 mg/5 mL 500 mg/50 mL (Pfizer/Hospira) (F)(PFL) no preservative[3]	N/A	10 mg/mL[3]	8 h[3]	syringe	8 h RT[3]	
				0.05–10 mg/mL **NS**, D5W, LR, Ringer's, D10W, D5NS[3] 50-250 mL†	**NS**, D5W, LR, Ringer's: 24 h RT[3] D10W, D5NS: 8 h RT[3]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Leucovorin 50 mg/5 mL 500 mg/50 mL (Teva) (F)(PFL) no preservative[4]	N/A	10 mg/mL[5]	discard unused portion[5]	syringe	8 h[6,7]	
				0.4 - 4.8 mg/mL **NS**, D5W[8] 50-250 mL†	72 h **F**, RT[8]	
				0.06 - 0.4 mg/mL **NS**, D5W[4] 50-250 mL†	**NS**: 24 h RT[4] D5W: 12 h RT[4]	
				0.06 - 1 mg/mL Ringer's, Lactated Ringer's, D10W, D10-NS[4]	Ringer's, LR: 24 h RT[4] D10W: 12 h RT[4] D10NS: 6 h RT[4]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Lurbinectedin 4 mg (Jazz) (F) no preservative[9]	8 mL SWI[9]	0.5 mg/mL[9]	12 h **F**, RT[9,10]	100-250 mL **NS**, D5W[9]	complete administration within 24 h **F**, RT[9]	- larger infusion volume is recommended for peripheral line[9] - do not use nylon membrane filters for administration if diluted in NS[9]; BD Alaris pumps and syringe sets have polyethersulfone membrane in-line filters[11]
Lurbinectedin 4 mg (Pharma Mar) (F) no preservative[12] (SAP)	8 mL SWI[12]	0.5 mg/mL[12]	12 h **F**, RT[10,12]	100–250 mL **NS**, D5W[12]	30 h **F**, RT[12]	- larger infusion volume is recommended for peripheral line[12]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Melphalan 50 mg (Marcan) (RT)(PFL) no preservative[13]	10 mL supplied diluent[13] rapidly add diluent and immediately shake vigorously to dissolve[13] record time of reconstitution	5 mg/mL[13]	2 h RT[13] **do NOT refrigerate**[13]	0.1-0.45 mg/mL **NS** only[13]	complete administration within 50 min RT from time of initial reconstitution[13]	- will precipitate if stored in fridge[13]
Melphalan 50 mg (Taro) (RT)(PFL) no preservative[14]	10 mL supplied diluent[14] rapidly add diluent and immediately shake vigorously to dissolve [14] record time of reconstitution	5 mg/mL[14]	2 h RT[14] **do NOT refrigerate**[14]	0.1-0.45 mg/mL **NS** only[14]	complete administration within 50 min RT from time of initial reconstitution[14]	- will precipitate if stored in fridge[14]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Mesna 400 mg/4 mL 1000 mg/10 mL (Baxter) (RT) no preservative[15]	N/A	100 mg/mL[15] (use filter needle to withdraw from ampoule)	discard unused portion[15]	≥1 mg/mL **NS**, D5W, D5½-NS, LR[15-17] 100 mL†	24 h RT[15]	
Mesna 1000 mg/10 mL 5000 mg/50 mL (Baxter) (RT) preservative[15]	N/A	100 mg/mL[15]	8 d RT[15] (vial may be punctured up to 4 times)[15]	≥1 mg/mL **NS**, D5W, D5½-NS, LR[15-17] 100 mL†	24 h RT[15]	
Mesna 1000 mg/10 mL (Fresenius Kabi) (RT) preservative[18]	N/A	100 mg/mL[18]	14 d **F, R**T[18,19]	≥1 mg/mL **NS**, D5W[20] 100 mL†	48 h F, 24 h RT[18]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Methotrexate 50 mg/2 mL 500 mg/20 mL 1 g/40 mL (Accord) (RT)(PFL) no preservative[21]	N/A	25 mg/mL[21]	50mg: discard unused portion[21] 500 mg, 1 g: 8 h RT[21]	syringe	use within 8 h RT of initial puncture[21]	- for high-dose regimens (e.g., 1-12 g/m^2 as a single dose): use preservative-free methotrexate[21] - do not use for IT injection
				0.4–2 mg/mL **NS**, D5W[21] 50-500 mL†	use within 24 h RT of initial puncture[21] **(PFL)	
				high dose (e.g., 1-12 g/m^2 as a single dose): 1000 mL* NS	use within 24 h RT of initial puncture[21] **(PFL)	
Methotrexate **<u>intravitreal injection</u>** 50 mg/2 mL (Accord) (RT)(PFL) no preservative[21]	N/A	25 mg/mL[21]	discard unused portion[21]	syringe for intravitreal use	use within 4 h of initial puncture[10]	- for intravitreal use preservative-free methotrexate is preferred[22]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Methotrexate **IT Injection** Only preservative free methotrexate may be administered by the intrathecal route[23] 50 mg/2 mL (Accord) (RT)(PFL) no preservative[21]	N/A	25 mg/mL[21]	discard unused portion[21]	IT syringe qs to 6 mL with preservative free NS[24,25] diluents containing preservatives should **NOT** be used for intrathecal administration[26]	use within 4 h of initial puncture[10]	- auxiliary info[10]: IT - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer Ziploc bag[27]
Methotrexate 50 mg/2 mL 500 mg/20 mL (Accord) (RT)(PFL) preservative[21]	N/A	25 mg/mL[21]	28 d F[10,21]	syringe	10 d **F**[10,21]	- contains benzyl alcohol[21] - do NOT use for high-dose regimens (e.g., 1-12 g/m^2 as a single dose)[21] - do NOT use for IT injection[21]
				0.4–2 mg/mL **NS**, D5W[21] 50-500 mL†	24 h RT[21]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Methotrexate 50 mg/2 mL 500 mg/20 mL 1 g/40 mL 2.5 g/100 mL (Pfizer/Hospira) (RT)(PFL) no preservative[28]	N/A	25 mg/mL[28]	50mg: discard unused portion[28] 500 mg, 1 g, or 2.5 g: 8 h RT[28]	syringe	use within 8 h RT of initial puncture[28]	- for high-dose regimens (e.g., 1-12 g/m^2 as a single dose): use preservative-free methotrexate[28] - do not use for IT injection
				0.4–2 mg/mL **NS**, D5W[28] 50-500 mL†	use within 24 h RT of initial puncture[28] **(PFL)	
				high dose (e.g., 1-12 g/m^2 as a single dose): 1000 mL* NS	use within 24 h RT of initial puncture[28] **(PFL)	
Methotrexate **<u>intravitreal injection</u>** 50 mg/2 mL (Pfizer/Hospira) (RT)(PFL) no preservative[28]	N/A	25 mg/mL[28]	discard unused portion[28]	syringe for intravitreal use	use within 4 h of initial puncture[10]	- for intravitreal use preservative-free methotrexate is preferred[22]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Methotrexate **IT Injection** Only preservative free methotrexate may be administered by the intrathecal route[23] 50 mg/2 mL (Pfizer/Hospira) (RT)(PFL) no preservative[28]	N/A	25 mg/mL[28]	discard unused portion[28]	IT syringe qs to 6 mL with preservative free NS[24,25] diluents containing preservatives should **NOT** be used for intrathecal administration[26]	use within 4 h of initial puncture[10]	- auxiliary info[10]: IT - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer Ziploc bag[27]
Methotrexate 50 mg/2 mL 500 mg/20 mL (Pfizer/Hospira) (RT)(PFL) preservative[28]	N/A	25 mg/mL[28]	28 d F[10,28]	syringe	10 d **F**[10,28]	- contains benzyl alcohol[28] - do NOT use for high-dose regimens (e.g., 1-12 g/m^2 as a single dose)[28] - do NOT use for IT injection[28]
				0.4–2 mg/mL **NS**, D5W[28] 50-500 mL†	24 h RT[28]	
Mitomycin 20 mg (Accord) (RT)(PFL) no preservative[29]	40 mL SWI[29] shake well[29]	0.5 mg/mL[29]	12 h F, 6 h RT[10,30] **(PFL)[30]	syringe	72 h F, 6 h RT[30] **(PFL)[30]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Mitomycin <u>intravesical</u> 20 mg (Accord) (RT)(PFL) no preservative[29]	40 mL SWI[29] shake well[29]	0.5 mg/mL[29]	12 h F, 6 h RT[10,30] **(PFL)[30]	syringe	72 h F, 6 h RT[30] **(PFL)[30]	
	10 mL SWI[31] shake well[29]	2 mg/mL[31]	use immediately after preparation to prevent precipitation[32]	syringe	use immediately after preparation to prevent precipitation[32]	- may precipitate due to low solubility[32,33] - do NOT refrigerate[32]
	25 mL SWI shake well	0.8 mg/mL[34]	discard unused portion[2,34] **(PFL)[2,34]	syringe	4 days RT[34] **(PFL)[2,34]	- do NOT refrigerate[34]
	33.3 mL SWI shake well	0.6 mg/mL[34]	discard unused portion[2,34] **(PFL)[2,34]	syringe	4 days **F**, RT[34] **(PFL)[2,34]	
Mitomycin <u>intraperitoneal</u> 20 mg (Accord) (RT)(PFL) no preservative[29]	40 mL SWI[29] shake well[29]	0.5 mg/mL[29]	12 h F, 6 h RT[10,30] **(PFL)[30]	0.02-0.04 mg/mL **NS**, sodium lactate[29]	NS: 18 h F, 3 h RT[30] sodium lactate: 6 h F, 3 h RT[30]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Mitomycin 20 mg (Teva) (RT)(PFL) no preservative[35]	40 mL SWI[35] shake well[35]	0.5 mg/mL[35]	12 h F, 6 h RT[10,35] **(PFL)[35]	syringe	72 h F, 6 h RT[35] **(PFL)[35]	
Mitomycin **<u>intravesical</u>** 20 mg (Teva) (RT)(PFL) no preservative[35]	40 mL SWI[35] shake well[35]	0.5 mg/mL[35]	12 h F, 6 h RT[10,35] **(PFL)[35]	syringe	72 h F, 6 h RT[35] **(PFL)[35]	
	10 mL SWI[31] shake well[35]	2 mg/mL[31]	use immediately after preparation to prevent precipitation[32]	syringe	use immediately after preparation to prevent precipitation[32]	- may precipitate due to low solubility[32,33] - do NOT refrigerate[32]
	25 mL SWI shake well	0.8 mg/mL[34]	discard unused portion[2,34] **(PFL)[2,34]	syringe	4 days RT[34] **(PFL)[2,34]	- do NOT refrigerate[34]
	33.3 mL SWI shake well	0.6 mg/mL[34]	discard unused portion[2,34] **(PFL)[2,34]	syringe	4 days **F**, RT[34] **(PFL)[2,34]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Mitomycin **intraperitoneal** 20 mg (Teva) (RT)(PFL) no preservative[35]	40 mL SWI[35] shake well[35]	0.5 mg/mL[35]	12 h F, 6 h RT[10,35] **(PFL)[35]	0.02-0.04 mg/mL **NS**, sodium lactate[35]	NS: 18 h F, 6 h RT[35] sodium lactate: 6 h **F**, RT[35]	
mitoXANTRONE 20 mg/10 mL (Fresenius Kabi) (RT) no preservative[36]	N/A	2 mg/mL[36]	discard unused portion[36]	0.2-0.6 mg/mL **NS**, D5W[36] 50 mL†	24 h RT[36]	
mitoXANTRONE 20 mg/10 mL 25 mg/12.5 mL 30 mg/15 mL (Pfizer/Hospira) (RT)(PFL) no preservative[37]	N/A	2 mg/mL[37]	discard unused portion[37]	0.2-0.6 mg/mL **NS**, D5W[37] 50 mL†	72 h F, 24 h RT[37] **(PFL)[37]	
Mogamulizumab 20 mg/5 mL (Kyowa) (F)(PFL) do not shake no preservative[38]	N/A	4 mg/mL[38]	discard unused portion[38]	0.1-3 mg/mL NS 100 mL* mix by gentle inversion; do not shake[38]	24 h F[38]	- discard if cloudy, discoloured, or visible particulates are present[38] - administer with 0.2 micron in-line filter[38]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Mogamulizumab 20 mg/5 mL (Kyowa) (F)(PFL) do not shake no preservative[39] (SAP)	N/A	4 mg/mL[39]	discard unused portion[39]	0.1-3 mg/mL NS[39] 100 mL* mix by gentle inversion; do not shake[39]	24 h F[39]	- discard if cloudy or discoloured[39] - administer with 0.2 micron in-line filter[39]
Nivolumab 40 mg/4 mL 100 mg/10 mL (BMS) (F)(PFL) do not shake no preservative[40]	N/A	10 mg/mL[40]	discard unused portion[40]	1-10 mg/mL **NS**, D5W[40] 25-100 mL† mix by gentle inversion; do not shake[40] OR undiluted in empty infusion bag or glass bottle[40]	complete administration within 7 days F, including max 8 h at RT[40] **(PFL)[40] (can be in room light when at RT)[40]	- do not shake[40] - administer with 0.2 micron in-line filter[40] - may contain a few amorphous particles[40] - discard if cloudy, has pronounced colour change (should be clear to pale yellow)[40]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
oBINutuzumab 1000 mg/40 mL (Roche) (F)(PFL)** do not shake no preservative[41]	N/A	25 mg/mL[41]	discard unused portion[42]	**NS** 100 mg: 100 mL[41] 900 mg: 250 mL[41] 1000 mg: 250 mL[41]	24 h **F**, 48 h RT[41,43]	-once removed from the fridge, diluted product is stable for an additional 48 h RT[41,43] - do NOT shake[41] - do NOT use dextrose containing solutions[41]
Octreotide 50 mcg/1 mL 100 mcg/1 mL 500 mcg/1 mL (Omega) (F)(PFL) no preservative[44]	N/A	50 mcg/mL[44] 100 mcg/mL[44] 500 mcg/mL[44]	discard unused portion[44]	NS[44] volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h[44]	24 h RT[44]	
Octreotide multidose vial: 1000 mcg/5 mL (Omega) (F)(PFL) preservative[44]	N/A	200 mcg/mL[44]	15 d F[44]	NS[44] volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h[44]	24 h RT[44]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Octreotide (SANDOSTATIN®) 50 mcg/1 mL 100 mcg/1 mL 500 mcg/1 mL (Novartis) (F)(PFL) no preservative[45]	N/A	50 mcg/mL[45] 100 mcg/mL[45] 500 mcg/mL[45]	discard unused portion[45]	NS[45] volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h[45]	24 h RT[45]	
Octreotide (SANDOSTATIN®) multi-dose vial: 1000 mcg/5 mL (Novartis) (F)(PFL) preservative[45]	N/A	200 mcg/mL[45]	14 d **F**, RT[45]	NS[45] volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h[45]	24 h RT[45]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Octreotide (SANDOSTATIN LAR®) (long acting) 10 mg 20 mg 30 mg (Novartis) (F)(PFL) no preservative[45]	2 mL supplied diluent[45] add diluent: gently run diluent down sides of vial[45] do NOT disturb for 2–5 min; then swirl moderately[45] record time of reconstitution	10 mg: 5 mg/mL[45] 20 mg: 10 mg/mL[45] 30 mg: 15 mg/mL[45]	discard unused portion[45]	syringe (for deep intragluteal administration only)[45]	use within 4 h of initial reconstitution[10,45]	- do NOT shake[45]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Octreotide suspension (long acting) 10 mg 20 mg 30 mg (Teva) (F)(PFL) no preservative[46]	2 mL supplied diluent let stand at RT for 30 min prior to reconstitution[46] add supplied diluent[46] let vial stand for 5 min after adding diluent to saturate powder[46] shake moderately in horizontal direction for ≥30 sec to create suspension[46] record time of reconstitution	10 mg: 5 mg/mL[46] 20 mg: 10 mg/mL[46] 30 mg: 15 mg/mL[46]	discard unused portion[46]	syringe (for deep intragluteal administration only)[46]	use within 4 h of initial reconstitution[10,46]	- gently shake to resuspend before administration[46] - delay in administration may result in sedimentation[46]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 200 mg/40 mL (Dr. Reddy's) (RT)(PFL) no preservative[47]	N/A	5 mg/mL[47]	discard unused portion[47]	0.2-0.7 mg/mL D5W[47] 100-500 mL† do **NOT** use NS or other chloride-containing solution[47] do **NOT** use aluminum-containing needle and syringe[47]	0.2-2 mg/mL: 48 h F, 24 h RT[47]	- do **NOT** use aluminum-containing needle, syringe, or tubing[47]
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 200 mg/40 mL (Pfizer/Hospira) (RT) no preservative[48]	N/A	5 mg/mL[48]	discard unused portion[48]	0.2-0.7 mg/mL D5W[48] 100-500 mL† do **NOT** use NS or other chloride-containing solutions[48] do **NOT** use aluminum-containing needle and syringe[48]	**0.2-0.4 mg/mL:** 24 h RT[48] or 5 d F plus an additional 8 h RT[49] **0.5–2 mg/mL:** 24 h RT[48] or 10 d F, plus an additional 8 h RT[10,49] **(PFL) when stored in F[49]	- do **NOT** use aluminum-containing needle, syringe, tubing[48]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 150 mg/30 mL 200 mg/40 mL (Sandoz) (RT)(PFL) no preservative[50]	N/A	5 mg/mL[50]	12 h **F**, RT[10,51]	0.2-0.7 mg/mL D5W[50] 100-500 mL† do **NOT** use NS or other chloride-containing solution[50] do **NOT** use aluminum-containing needle and syringe[50]	0.2-2 mg/mL: 48 h F, 24 h RT[50]	- do **NOT** use aluminum-containing needle, syringe, tubing[50]
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 200 mg/40 mL (Teva) (RT)(PFL) no preservative[52]	N/A	5 mg/mL[52]	discard unused portion[52]	0.2-0.7 mg/mL D5W[52] 100-500 mL† do **NOT** use NS or other chloride-containing solution[52] do **NOT** use aluminum-containing needle and syringe[52]	0.2-2 mg/mL: 48 h F, 24 h RT[52]	- do **NOT** use aluminum-containing needle, syringe or tubing[52]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
PACLitaxel 30 mg/5 mL 100 mg/16.7 mL 300 mg/50 mL (Accord) (RT)(PFL) preservative[53]	N/A	6 mg/mL[53]	30 mg, 100 mg: 28 d RT[10,53] 300 mg: 24 h RT[10,53]	0.3-1.2 mg/mL **NS**, D5W, D5NS, D5LR[53] 50-500 mL†	complete administration within 27 h RT[53]	- use non-DEHP bag and tubing [53] - administer with 0.2 micron in-line filter[53] - avoid excessive shaking[53]
				0.1 mg/mL **NS**[54]	44 h **F**, RT[54]	
PACLitaxel 30 mg/5 mL 100 mg/16.7 mL 300 mg/50 mL (Biolyse) (RT) preservative[55]	N/A	6 mg/mL[55]	28 d RT[56]	0.3-1.2 mg/mL **NS,** D5W[55] 50-500 mL†	complete administration within 27 h RT[57,58]	- use non-DEHP bag and tubing [55] - administer with 0.2 micron in-line filter[55]
				0.1 mg/mL **NS**[54]	44 h **F**, RT[54]	
				0.012-0.12 mg/mL **NS**[59]	16 h RT[57]	
				devices with spikes (e.g., chemo dispensing pins) **may be used** with vials[60]		

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Paclitaxel 30 mg/5 mL 100 mg/16.7 mL 300 mg/50 mL (Sandoz) (RT)(PFL) preservative[61]	N/A	6 mg/mL[61]	30 mg, 100 mg: 28 d RT[10,61] 300 mg: 24 h RT[10,61]	0.3-1.2 mg/mL **NS**, D5W, D5NS[61] 50-500 mL†*	complete administration within 27 h RT[61]	- use non-DEHP bag and tubing[61] - administer with 0.2 micron inline filter[61] - avoid excessive shaking
				0.1 mg/mL **NS**[54]	44 h **F**, RT[54]	
PACLitaxel, nanoparticle, albumin-bound (NAB) 100 mg (Celgene) (RT)(PFL) no preservative[62]	20 mL NS[62] slowly direct diluent against side of vial (i.e., ≥1 min) during reconstitution[62] let stand for ≥5 min to wet powder[62] gently swirl or invert for ≥2 min[62]	5 mg/mL[62]	use immediately (RT) or 8 h F[62] **(PFL)[62]	in empty sterile PVC, non-PVC, or non-DEHP infusion bag[62]	48 h F plus an additional 8 h RT[63]	- each vial contains 900 mg human albumin[62] - to prevent foaming, do NOT inject NS directly onto the powder[62] - some settling may occur; use mild agitation to resuspend[62] - administer with 15 micron filter ONLY[62] (NOTE: filters with pore size less than 15 microns may cause filter blockage)[64]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
PACLitaxel, nanoparticle, albumin-bound (NAB) 100 mg (Panacea/Apo) (RT)(PFL) no preservative[65]	20 mL NS[65] slowly direct diluent against side of vial (i.e., ≥1 min) during reconstitution[65] let stand for ≥5 min to wet powder[65] gently swirl or invert for ≥2 min[65] (if foaming occurs, let stand for ≥15 min)[65]	5 mg/mL[65]	use immediately (RT) or 8 h F[65] **(PFL)[65]	in empty sterile PVC, non-PVC, or non-DEHP infusion bag[65]	56 h F plus an additional 4 h RT[66]	- each vial contains 900 mg human albumin[65] - to prevent foaming, do NOT inject NS directly onto the powder[65] - some settling may occur; use gentle inversion to resuspend[65] - discard if visible particulates are present[65] - administer with 15 micron filter ONLY[65]
Pamidronate 30 mg/10 mL 60 mg/10 mL 90 mg/10 mL (Fresenius Kabi) (RT) no preservative[67]	N/A	3 mg/mL[67] 6 mg/mL[67] 9 mg/mL[67]	discard unused portion[67]	≤0.36 mg/mL[67] **NS**, D5W[67] 250 mL†	24 h RT[67]	- do **NOT** mix with calcium containing solutions (e.g., Lactated Ringer's)[67]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Pamidronate 30 mg/10 mL 60 mg/10 mL 90 mg/10 mL (Hospira) (RT) no preservative[68]	N/A	3 mg/mL[68]	discard unused portion[68]	0.06–0.36 mg/mL **NS**, D5W[68] 250 mL†	24 h F plus an additional 24 h RT (total 48 h)[68] **(PFL)[68]	- do **NOT** mix with calcium containing solution (e.g., Lacated Ringer's)[68]
		6 mg/mL[68]				
		9 mg/mL[68]				
Pamidronate 30 mg/10 mL 60 mg/10 mL 90 mg/10 mL (Omega) (RT) no preservative[69]	N/A[69]	3 mg/mL[69]	discard unused portion[69]	0.06–0.36 mg/mL **NS**, D5W[69] 250 mL†	24 h F plus an additional 24 h RT (total 48 h)[69] **(PFL)[69]	- do **NOT** mix with calcium containing solution (e.g., Lactated Ringer's)[69]
		6 mg/mL[69]				
		9 mg/mL[69]				
Pamidronate 30 mg/10 mL 60 mg/10 mL 90 mg/10 mL (Pfizer) (RT) no preservative[70]	N/A	3 mg/mL[70]	discard unused portion[70]	0.06-0.36 mg/mL **NS**, D5W[70] 250 mL†	24 h F plus an additional 24 h RT (total 48 h)[70] **(PFL)[70]	- do **NOT** mix with calcium containing solution (e.g., Lactated Ringer's)[70]
		6 mg/mL[70]				
		9 mg/mL[70]				

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Pamidronate 30 mg/10 mL 60mg/10 mL 90 mg/10 mL (Sandoz Canada) RT no preservative[71]	N/A	3 mg/mL[71]	discard unused portion[71,72]	**NS**; D5W[71] 250 mL†	24 h RT[71]	- do **NOT** mix with calcium containing solution (e.g., Lactated Ringer's)[71]
		6 mg/mL[71]				
		9 mg/mL[71]				
PANitumumab 100 mg/5 mL 400 mg/20 mL (Amgen) (F)(PFL) do not shake no preservative[73]	N/A	20 mg/mL[73]	discard unused portion[73]	1-10mg/mL NS[73] 100 mL†	24 h F, 6 h RT[73-76]	- administer with 0.2 micron in-line filter[73] - solution may contain particulates which do not affect product quality[73] - do not administer if discoloured[73]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Pegaspargase (pegylated asparaginase *E. coli*) 3750 units/5 mL (Servier) (F)(PFL) do not shake no preservative[77]	N/A	750 units/mL[77]	discard unused portion[77]	IM[77]: max volume: 2 mL in children and adolescents; 3 mL in adults if volume greater than above, use multiple sites[77]	syringe: use within 4 h of vial puncture[2,77]	- do NOT shake[77]
				IV[77]: 100 mL **NS**, D5W	bag: use within 4 h of vial puncture[2,77]	
Pembrolizumab 100 mg/4 mL (Merck) (F)(PFL) do not shake no preservatives[78]	N/A	25 mg/mL[78]	discard unused portion[2,78]	1-10 mg/mL **NS**, D5W[78] 50 mL* mix by gentle inversion[78]	complete administration within 96 h F, 6 h RT[78]	- administer with 0.2 micron in-line filter[78] - bring vials and diluted solutions to RT prior to use[78] - vials contain 0.25 mL overfill[78]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Pemetrexed 100 mg 500 mg (Accord) (RT) no preservative[79]	100 mg: 4.2 mL NS[79] 500 mg: 20 mL NS[79]	25 mg/mL[79]	12 h **F**, RT[10,79]	100 mL NS[79]	24 h **F**, RT[79]	- do **NOT** mix with calcium containing solution (e.g., Ringer's)[79]
Pemetrexed 100 mg/4 mL 500 mg/20 mL 850 mg/34 mL 1000 mg/40 mL (Accord) (RT)(PFL) no preservative[80]	N/A	25 mg/mL[80]	discard unused portion[80]	100 mL NS[80]	24 h F[80]	- do **NOT** mix with calcium containing solution (e.g., Ringer's)[80]
Pemetrexed 100 mg 500 mg (Dr. Reddy's) (RT) no preservative[81]	100 mg: 4.2 mL NS[81] 500 mg: 20 mL NS[81]	25 mg/mL[81]	12 h **F**, RT[10,82-84]	100 mL NS[81]	24 h **F**, RT[82-84]	- do **NOT** mix with calcium containing solution (e.g., Ringer's)[81]
Pemetrexed 100 mg 500 mg (Lilly) (RT) no preservative[85]	100 mg: 4.2 mL NS[85] 500 mg: 20 mL NS[85]	25 mg/mL[85]	12 h **F**[10,85]	100 mL NS[85]	24 h **F**[85]	- do **NOT** mix with calcium containing solution (e.g., Ringer's)[85]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Pemetrexed 100 mg 500 mg 1000 mg (Taro) (RT) no preservative[86]	100 mg: 4.2 mL NS[86] 500 mg: 20 mL NS[86] 1000 mg: 40 mL NS[86]	25 mg/mL[86]	12 h F[10,86]	100 mL NS[86]	24 h F[86]	- do **NOT** mix with calcium containing solution (e.g., Ringer's)[86]
Pentostatin 10 mg (Hospira/Pfizer) (F) no preservative[87]	5 mL SWI[87]	2 mg/mL[87]	8 h RT[87]	0.18-0.33 mg/mL[87] 25-50 mL **NS**, D5W[87]	8 h RT[87]	
PERTuzumab 420 mg/14 mL (Roche) (F)(PFL) no preservative[88]	N/A	30 mg/mL[88] do NOT shake[88]	discard unused portion[42,88]	250 mL **NS** only[88] mix by gentle inversion to avoid foaming[88]	24 h **F**, RT[88]	- do NOT use dextrose containing solutions[88]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
PERTuzumab-trastuzumab 1200 mg-600 mg/15 mL 600 mg-600 mg/10 mL (Roche) (F)(PFL) do not shake no preservative[89]	N/A	**1200 mg-600 mg[89]:** 80 mg/mL pertuzumab and 40 mg/mL trastuzumab **600 mg-600 mg[89]:** 60 mg/mL pertuzumab and 60 mg/mL trastuzumab	discard unused portion[89]	SC syringe[89]	10 d F, 24 h RT[10,89]	- do not shake[89] - contains recombinant human hyaluronidase[89]
Plerixafor 24 mg/1.2 mL (sanofi-aventis) (RT) no preservative[90]	N/A	20 mg/mL[90]	discard unused portion[90]	SC syringe[90]	48 h RT[72,91]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Polatuzumab vedotin 30 mg 140 mg (Hoffman-La Roche) (F)(PFL) do not shake no preservative[92]	30 mg: 1.8 mL SWI[92] 140 mg: 7.2 mL SWI[92] direct diluent against side of vial during reconstitution[92] swirl gently to mix[92]	20 mg/mL[92] (PFL)	12 h F, RT[10,92]	0.72-2.7 mg/mL **NS**, D5W, ½NS[92] (dilute to a minimum volume of 50 mL) [92] gently invert bag to mix[92]	in NS: 72 h **F**, 4 h RT[92] in D5W or ½NS: 72 h **F**, 8 h RT[92]	- do NOT shake[92] - administer with 0.2 micron in-line filter[92] -discard if discolouration or visible particulates are present[92]
Pralatrexate 20 mg/1 mL 40 mg/2 mL (Servier) (F)(PFL) no preservative[93]	N/A	20 mg/mL[93]	discard unused portion[2]	syringe[93]	24 h **F**, RT[94] **(PFL)[94]	- do NOT dilute[93]
Raltitrexed 2 mg (Pfizer) (**F**,RT)(PFL) no preservative[95]	4 mL SWI[95]	0.5 mg/mL[95]	12 h **F**, RT[10,95]	50-250 mL **NS**, D5W[95]	complete administration within 24 h **F**, RT[95]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Ramucirumab 100 mg/10 mL 500 mg/50 mL (Eli Lilly) (F)(PFL) (do not shake) no preservative[96]	N/A	10 mg/mL[96]	discard unused portion[96]	0.4–4 mg/mL NS[96,97] 250-500 mL† gently invert to mix[96] do NOT shake[96]	24 h F, 4 h RT[96]	- administer with 0.2 micron in-line filter[96] - do NOT use dextrose containing solutions[96]
riTUXimab (RITUXAN®) 100 mg/10 mL 500 mg/50 mL (Roche) (F)(PFL) no preservative[98]	N/A	10 mg/mL[98]	discard unused portion[98]	1-4 mg/mL **NS**, D5W[98] 250-500 mL†	**NS:** 10 d F plus an additional 24 h RT[10,98] **D5W:** 24 h F plus an additional 12 h RT[98]	
riTUXimab intravitreal injection (RITUXAN®) 100 mg/10 mL (Roche) (F)(PFL) no preservative[98]	N/A	10 mg/mL[98]	discard unused portion[98]	syringe for intravitreal use	use within 4 h of initial puncture[10]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
riTUXimab **subcutaneous** (**RITUXAN® SC**) 1400 mg/11.7 mL 1600 mg/13.4 mL (Roche) (F)(PFL) no preservative[99]	N/A	120 mg/mL[99]	discard unused portion[99]	SC syringe[99]	48 h F plus 8 h RT[99]	- contains hyaluronidase[99] - formulations are NOT interchangeable[99]
riTUXimab (**RIXIMYO®**) 100 mg/10 mL 500 mg/50 mL (Sandoz) (F)(PFL) (do NOT shake) no preservative[100]	N/A	10 mg/mL[100]	discard unused portion[100]	1-4 mg/mL **NS**, D5W[100] 250-500 mL† gently invert to mix	**NS**: 10 d F plus an additional 24 h RT[10,100] **D5W**: 24 h F plus an additional 12 h RT[100]	
riTUXimab **intravitreal injection** (**RIXIMYO®**) 100 mg/10 mL (Sandoz) (F)(PFL) (do NOT shake) no preservative[100]	N/A	10 mg/mL[100]	discard unused portion[100]	syringe for intravitreal use	use within 4 h of initial puncture[10]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
riTUXimab (**RUXIENCE®**) 100 mg/10 mL 500 mg/50 mL (Pfizer) (F)(PFL) no preservative[101]	N/A	10 mg/mL[101]	discard unused portion[101]	1-4 mg/mL **NS**, D5W[101] 250-500 mL† gently invert to mix	24 h F plus an additional 24 h RT[101]	
riTUXimab **intravitreal injection** (**RUXIENCE®**) 100 mg/10 mL 500 mg/50 mL (Pfizer) (F)(PFL) no preservative[101]	N/A	10 mg/mL[101]	discard unused portion[101]	syringe for intravitreal use	use within 4 h of initial puncture[10]	
riTUXimab (**TRUXIMA®**) 100 mg/10 mL 500 mg/50 mL (Teva/Celltrion) (F)(PFL) no preservative[102]	N/A	10 mg/mL[102]	discard unused portion[102]	1-4 mg/mL **NS**, D5W[102] 250-500 mL† gently invert to mix	24 h F plus an additional 12 h RT[102]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
riTUXimab **intravitreal injection** (**TRUXIMA®**) 100 mg/10 mL 500 mg/50 mL (Teva/Celltrion) (F)(PFL) no preservative[102]	N/A	10 mg/mL[102]	discard unused portion[102]	syringe for intravitreal use	use within 4 h of initial puncture[10]	
romiDEPsin 10 mg (Celgene Inc.) (RT)[103] no preservative[42]	2.2 mL supplied diluent[103,104] swirl gently to mix[103]	5 mg/mL[103]	8 h RT[103]	500 mL NS[103]	24 h RT[103]	- reconstituted solution will be slightly viscous[105] - vials contain overfill to allow for full drug recovery (drug vial contains 11 mg romidepsin; diluent vial contains 2.4 mL diluent)[103]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Sacituzumab govitecan 180 mg (Gilead) (F)(PFL) no preservative[106]	20 mL NS[106] bring vials to RT before reconstitution[106] slowly add diluent to vial and gently swirl; allow to dissolve for up to 15 min[106] do not shake[106]	10 mg/mL[106]	use immediately after reconstitution to prepare infusion solution[106] discard unused portion[106]	1.1-3.4 mg/mL NS[106] 100-1000 mL NS† slowly inject solution to bag to minimize foaming; do not shake[106]	24 h F[106], plus an additional 8 h RT including infusion time[106] **(PFL)[106]	- do not shake[106] - protect container from light during administration[106] - vials contain overfill (~20 mg per vial)[107]
Siltuximab 100 mg 400 mg (Janssen) (F)(PFL) no preservative[108]	100 mg: 5.2 mL SWI[108] 400 mg: 20 mL SWI[108] bring vial to RT prior to use (~30 min)[108] gently swirl, do NOT shake[108]	20 mg/mL[108]	2 h RT[108]	250 mL D5W[108] dilute to final volume by withdrawing volume from bag equal to volume of drug to be added[108]	complete administration within 6 h RT[108]	- administer with 0.2 micron in-line filter[108]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Sirolimus, nanoparticle, albumin-bound (NAB) 100 mg (Aadi) (F)(PFL) no preservative[109] (SAP)	20 mL NS[109] slowly direct diluent against side of vial (over ≥1 min)[109] let stand for ≥5 min to wet powder[109] gently swirl or invert for ≥2 min to avoid foaming[109] if foaming/clumping occurs, let stand until foam subsides (≥15 min)[109]	5 mg/mL[109]	4 h F[110,111] **(PFL)[109]	undiluted in empty PVC or non-PVC infusion bag[109]	9 h F, followed by max 4 h RT[109] **(PFL)[109]	- each vial contains ~800-900 mg human albumin[109,112] - to prevent foaming, do NOT inject NS directly onto the powder[109] - if powder is visible after reconstitution, gently invert to resuspend powder[109] - to prevent administration of proteinaceous strands, administer with 15 micron filter ONLY[109]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Streptozocin 1g (Keocyt) (F)(PFL) no preservative[113-116] (SAP)	9.5mL **NS,** SWI, D5W[113-116]	100 mg/mL[113-116]	12 h F[10,114-116]	syringe[114-116]	48 h F[10,114-116]	
				100-500 mL **NS**, D5W, SWI[113-116]	24 h F[114-116]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Tebentafusp 100 mcg/0.5 mL (Immunocore/Medison) (F)(PFL) do not shake no preservative[117]	N/A	200 mcg/mL[117]	discard unused portion[117]	100 mL NS[117] Step 1: add calculated volume of human albumin 5% to provide 225-275 mcg/mL final concentration[117] to mix: invert the bag and gently rotate ≥5 times; do NOT shake bag (repeat x3)[117] Step 2: add calculated volume of drug[117] to mix: invert the bag and gently rotate ≥5 times; do NOT shake bag (repeat x3)[117]	complete administration within 24 h F, 4 h RT[117] bring to RT prior to administration[117]	- do NOT use CSTD or filters during **preparation**[117] - CSTD can be used for administration[118] - administer using 0.2 micron in-line filter[117] - once the bag has been removed from fridge, it must remain at RT[117]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Tebentafusp 100 mcg/0.5 mL (Immunocore/Clinigen) (F)(PFL) do not shake no preservative[119,120] (SAP)	N/A	200 mcg/mL[119]	discard unused portion[2,119,120]	100 mL NS[119,120] Step 1: add calculated volume of human albumin 5% to provide 225-275 mcg/mL final concentration[119,120] to mix: invert the bag and gently rotate ≥5 times; do NOT shake bag (repeat x3)[119,120] Step 2: add calculated volume of drug[119,120] to mix: invert the bag and gently rotate ≥5 times; do NOT shake bag (repeat x3)[119,120]	complete administration within 24 h F, 4 h RT[119,120]	- do NOT use CSTD or filters during **preparation**[119] - CSTD can be used for administration[118] - administer using 0.2 micron in-line filter[119,120] - once the bag has been removed from fridge, it must remain at RT[119,120]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Teclistamab 30 mg/3 mL 153 mg/1.7 mL (Janssen) (F)(PFL) do not shake no preservative[121]	N/A	30 mg[121]: 10 mg/mL (use for 2.1-52.9 mg doses)* 153 mg[121]: 90 mg/mL (use for 53-375 mg doses)* bring to RT before use (~15 min)[121] swirl gently for 10 sec to mix; do NOT shake[121]	discard unused portion[121]	SC syringe[121] if drug volume >2 mL, divide volume into separate syringes for administration[121]	20 h **F**, RT[121] if stored in fridge, bring to RT prior to administration[121]	- **CAUTION**: two concentrations are available[121] - CSTD must not be used for preparation or administration of syringe volumes less than 1 mL[122]; use filtered venting needle (e.g., Chemo-Vent®) in place of CSTD for preparation[123]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Temsirolimus 30 mg/1.2 mL (Pfizer/Wyeth) (F)(PFL)[124] no preservative[125]	1.8 mL supplied diluent[124]	10 mg/mL[124]	12 h RT[10,124] **(PFL)[124]	250 mL NS[124] record time of dilution[124]	complete administration within 6 h[124] mix by gentle inversion to avoid foaming[124]	- use non-DEHP bag and tubing - administer with 0.2 micron in-line filter[124]
Teniposide 50 mg/5 mL (BMS) (RT) preservative[126]	N/A	10 mg/mL[126]	discard unused portion	0.1-1 mg/mL **NS,** D5W[126] 50–500 mL*	0.1-0.4 mg/mL: 24 h RT[126] 1 mg/mL: complete administration within 4 h RT of preparation[126,127]	- do not refrigerate - use non-DEHP bag and tubing[126] - do not use if precipitates[126,127] - contains DMA*** - excessive agitation may cause precipitation[126]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Thiotepa 15 mg 100 mg (Adienne/Methapharm) (F) no preservative[128] (SAP)	**15 mg:** 1.5 mL SWI[128] **100 mg:** 10 mL SWI[128] to remove haze, filter through 0.22 micron filter after reconstitution[129] record time of reconstitution	10 mg/mL[128]	8 h F[128]	0.5-1 mg/mL NS[128] ≤500 mg: 500 mL[128] >500 mg: 1000 mL[128] reconstituted solution is hypotonic and must be further diluted with NS prior to use[128]	24 h F, 4 h RT[128]	- do not use if precipitates are present[128] - reconstituted solution may be used if opalescent[128] - administer with 0.2 micron in-line filter[128]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Thiotepa **IT injection** 15 mg 100mg (Adienne/Methapharm) (F) no preservative[128] (SAP)	**15 mg:** 1.5 mL SWI[128] **100 mg:** 10 mL SWI[128] diluents containing preservatives should **NOT** be used for intrathecal administration[26] to remove haze, filter through 0.22 micron filter after reconstitution[129] record time of reconstitution	10 mg/mL[128]	8 h F[128]	IT syringe qs to 6 mL with preservative free NS[130] diluents containing preservatives should **NOT** be used for intrathecal administration[26]	use within 4 h of initial reconstitution[2]	- auxiliary info[27]: IT - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag[27] - do not use if precipitates are present[128] - reconstituted solution may be used if opalescent[128]
Thyrotropin alfa 1.1 mg (Genzyme) (F)(PFL) no preservative[131]	1.2 mL SWI[131] swirl gently to mix[131] do NOT shake[131]	0.9 mg/mL[131]	12 h F[10,131]	syringe[131]	24 h F[10,131]	- do not use if particulates are present[131]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Tislelizumab 100 mg/10 mL (BeiGene) (F)[132,133] (do not shake) no preservative[134] (SAP)	N/A	10 mg/mL[134]	discard unused portion[134]	1-10 mg/mL NS[134] 50-100 mL*	complete administration within 20 h F, 4 h RT (max 24 h from preparation)[134] bring to RT prior to administration[134] mix by gentle inversion; do not shake[134]	
Tocilizumab 80 mg/4 mL 200 mg/10 mL 400 mg/20 mL (Roche) (F)(PFL) no preservative[135]	N/A	20 mg/mL[135]	discard unused portion[135]	100 mL NS[135] dilute to final volume by withdrawing volume from bag equal to volume of drug to be added[135] gently invert to mix[135]	complete administration within 24 h **F**, RT[135] bring to RT prior to administration[135]	- to prevent foaming: slowly add drug to infusion bag and gently invert bag to mix[135]
Topotecan 4 mg/4 mL (Accord) (RT)(PFL) no preservative[136]	N/A	1 mg/mL[136]	12 h **F**, RT[10,136]	0.025-0.5 mg/mL **NS**, D5W[136] 25-50 mL†	10 d F, 4 d RT[10,136]	

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Topotecan 4 mg/4 mL (Pfizer/Hospira) (F)(PFL) no preservative[137]	N/A	1 mg/mL[137]	discard unused portion[137]	0.02-0.5 mg/mL **NS**, D5W[137] 25-50 mL†	24 h **F**, RT[137]	
Topotecan 4 mg/4 mL (Sandoz) (F)(PFL) no preservative[138]	N/A	1 mg/mL[138]	discard unused portion[138]	0.02-0.5 mg/mL **NS**, D5W[138] 25-50 mL†	24 h F[138] **(PFL)[138]	
Trastuzumab (HERCEPTIN®) 440 mg (Roche) (F) no preservative[139]	20 mL supplied BWI[139] swirl vial gently; allow to stand undisturbed for 5 min[139]	21 mg/mL[139]	28 d F[139]	250 mL **NS** only[139] do NOT use dextrose containing solutions[139]	24 h **F**, RT[139]	- do NOT shake[139]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Trastuzumab (HERZUMA®) 150 mg 440 mg (Teva/Celltrion) (F) no preservative[140]	150 mg: 7.2 mL SWI[140]	21 mg/mL[140]	discard unused portion[140]	250 mL **NS** only[140] do **NOT** use dextrose containing solutions[140]	24 h **F**, RT[140]	- do NOT shake[140] - supplied BWI contains benzyl alcohol[140]
	440 mg: 20 mL supplied BWI[140]		28 d F[140]			
	swirl vial gently; allow to stand undisturbed for 5 min[140]					
Trastuzumab (OGIVRI®) 150 mg 440 mg (BGP) (F) no preservative[141]	150 mg: 7.2 mL SWI[141]	21 mg/mL[141]	discard unused portion[141]	250 mL **NS** only[141] do **NOT** use dextrose containing solutions[141]	24 h **F**, RT[141]	- do NOT shake[141] - supplied BWI contains benzyl alcohol[141]
	440 mg: 20 mL supplied BWI[141]		28 d F[141]			
	swirl vial gently; allow to stand undisturbed for 5 min[141]					

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Trastuzumab (TRAZIMERA®) 150 mg 440 mg (Pfizer) (F) no preservative[142]	150 mg: 7.2 mL SWI[142]	21 mg/mL[142]	discard unused portion[142]	250 mL **NS** only[142] do **NOT** use dextrose containing solutions[142]	24 h **F**, RT[142]	- do NOT shake[142] - supplied BWI contains benzyl alcohol[142]
	440 mg: 20 mL supplied BWI[142]		28 d F[142]			
	swirl vial gently; allow to stand undisturbed for 5 min[142]					

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Trastuzumab deruxtecan (ENHERTU®) 100 mg (AstraZeneca) (F)(PFL) no preservative[143]	5 mL SWI[143] swirl gently until completely dissolved[143] do NOT shake[143]	20 mg/mL[143]	12 h F[10,143] **(PFL)[143]	100 mL D5W only[143] gently invert to mix[143] do NOT shake[143] do **NOT** use sodium chloride solution[143]	complete administration within 24 h F, 4 h RT[143] **(PFL)[143]	- do not use if reconstituted solution contains visible particulates or is cloudy or discoloured[143] - protect container from light during administration[144] - administer with 0.2 micron in-line filter[143] - if stored in fridge, bring bag to RT prior to use[143]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Trastuzumab emtansine (KADCYLA®) 100 mg 160 mg (Roche) (F)(PFL) no preservative[145]	100 mg: 5 mL SWI[145] 160 mg: 8 mL SWI[145] swirl gently until completely dissolved do NOT shake[145]	20 mg/mL[145]	12 h **F**[10,146]	250 mL **NS** or ½NS only[145] do NOT shake[145] do **NOT** use dextrose containing solutions[145]	24 h F[145]	- do not use if reconstituted solution contains visible particulates or is cloudy or discolored[145] - D5W causes aggregation of the protein[145] - for infusions prepared in NS: administer with 0.2 micron in-line filter or 0.22 micron polyethersulfane (PES) filter[145] - for infusions prepared in ½NS: filter is optional for administration[145]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Treosulfan 1 g 5 g (Medexus) (RT) no preservative[147]	1 g[147]: 20 mL NS, D5W, SWI, ½NS 5 g[147]: 100 mL NS, D5W, SWI, ½NS **pre-heat** diluent to 25-30°C (max)[148] **shake vial** to loosen powder before adding the warmed diluent[149] vigorous shaking may be required[149]; prolonged standing time may improve solubility[147]	50 mg/mL[147]	12 h RT[10,147]	undiluted in empty infusion bag[147,148]	3 d RT[147]	- do NOT refrigerate as may precipitate[147]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Treosulfan 1 g 5 g (medac) (RT) no preservative[150,151] (SAP)	1 g[150,151]: 20 mL SWI, ½NS 5 g[150,151]: 100 mL SWI, ½NS pre-heat diluent to 25-30°C (max)[150,151] shake vial carefully to loosen powder before adding the warmed diluent[150,151] gently shake while adding diluent[150,151] (takes ~2 min to reconstititute)[150,151]	50 mg/mL[150,151]	12 h RT[10,150,152]	undiluted[153] or dilute with **NS** or D5W in empty infusion bag for final concentration = 20 mg/mL[152]	4 d RT[150,152]	- compatible with polytetrafluoroethylene filters[154] - may sometimes require vigorous shaking to reconstitute[150,151] - do NOT refrigerate as may cause precipitation[150,151]
vinBLAStine 10 mg/10 mL (Pfizer) (F)(PFL) no preservative[155]	N/A	1 mg/mL[155]	discard unused portion[2,155]	25-50 mL **NS**, D5W[156]	use within 4 h of initial vial puncture[2,155]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[157,158]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
vinBLAStine 10 mg/10 mL (Teva) (F)(PFL) no preservative[159]	N/A	1 mg/mL[159]	discard unused portion[2,159]	25-50 mL **NS**, D5W[156]	use within 4 h of initial vial puncture[2,159]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[157,158]
vinCRIStine 2 mg/2 mL 5 mg/5 mL (Pfizer/Hospira) (F)(PFL) no preservative[160]	N/A	1 mg/mL[160]	8 h F, RT[160]	0.01-0.1 mg/mL **NS**, D5W[160] 50 mL†	24 h F, RT[160] **(PFL)[160]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[157,158] - for LYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing either etoposide or etoposide phosphate AND DOXOrubicin and vinCRIStine)

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
vinCRIStine 1 mg/1 mL 2 mg/2 mL 5 mg/5 mL (Teva) (F)(PFL) no preservative[161]	N/A	1 mg/mL[161]	8 h **F**, RT[161]	0.01-0.1 mg/mL **NS**, D5W[161] 50 mL†	24 h F, RT[161]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[157,158] - for LYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing either etoposide or etoposide phosphate AND DOXOrubicin and vinCRIStine)
Vinorelbine 10 mg/1 mL 50 mg/5mL (Fresenius Kabi) (F)(PFL) no preservative[162]	N/A	10 mg/mL[162]	discard unused portion[162]	0.5-2.0 mg/mL **NS**, D5W, ½NS, D5-½NS, Ringer's, Ringer's Lactate[162] 50 mL†	24 h **F**, RT[162]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[157,158]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Vinorelbine 10 mg/1 mL 50 mg/5 mL (GMP) (F)(PFL) no preservative[163]	N/A	10 mg/mL[163]	discard unused portion[2]	0.5-2.0 mg/mL **NS**, D5W, ½NS, D5-½NS, Ringer's, Ringer's Lactate[163] 50 mL†	24 h **F**, RT[163]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[157,158]
Vinorelbine 10 mg/1 mL 50 mg/5 mL (Teva) (F)(PFL) no preservative[164]	N/A	10 mg/mL[164]	discard unused portion[164]	0.5–2.0 mg/mL **NS**, D5W, ½NS, D5-½NS, Ringer's, Ringer's Lactate[164] 50 mL†	24 h **F**, RT[164]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[157,158]
Zoledronic acid 4 mg/5 mL (Dr Reddy's) (RT) no preservative[165]	N/A	0.8 mg/mL[165]	discard unused portion[165]	100 mL **NS**, D5W[165]	complete infusion within 24 h of preparation[165] **refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use[165]	- do **NOT** mix with calcium containing solutions (e.g., Lactated Ringer's)[165]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Zoledronic acid 4 mg/5 mL (Marcan) (RT) no preservative[166]	N/A	0.8 mg/mL[166]	discard unused portion[166]	100 mL **NS**, D5W[166]	complete infusion within 24 h of preparation[166] **refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use[166]	- do **NOT** mix with calcium containing solutions (e.g., Lactated Ringer's)[166]
Zoledronic acid 4 mg/5 mL (MDA) (RT) no preservative[167]	N/A	0.8 mg/mL[167]	discard unused portion[167]	100 mL **NS**, D5W[167]	complete infusion within 24 h of preparation[167] **refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use[167]	- do **NOT** mix with calcium containing solutions (e.g., Lactated Ringer's)[167]

Activation Date: 2 March 2006
Revised Date: 1 March 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Zoledronic acid (ZOMETA) 4 mg/ 5 mL (Novartis) (RT) no preservative[168]	N/A	0.8 mg/mL[168]	discard unused portion[42]	100 mL **NS,** D5W[168]	complete infusion within 24 h of preparation[168] **refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use[168]	- do NOT mix with calcium containing solutions (e.g., Lactated Ringer's)[168]
Zoledronic acid 4 mg/5 mL (Sandoz) (RT) no preservative[169]	N/A	0.8 mg/mL[169]	discard unused portion[169]	100 ml **NS**, D5W[169]	complete infusion within 24 h of preparation[169] **refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use[169]	- do NOT mix with calcium containing solutions (e.g., Lactated Ringer's)[169]

* Suggested volume based on usual dose range and any concentration range of stability data
† see BC Cancer IV Bag Selection table: standardized bag sizes are provided for select Benefit Drugs with concentration-dependent stability or large drug volume
** Protect from light means minimizing exposure to direct sunlight over a *storage* period. More specific information on protection from light (eg, protecting container and tubing during *administration*) will be indicated in the Special Precautions/Notes column.
*** Contains DMA (N,N dimethylacetamide). Product may be incompatible with closed system transfer devices (CSTD) such as ChemoLock.

Centres are not to change content locally. All suggestions for change are to be forwarded to the Cancer Drug Manual editor.

Activation Date: 2 March 2006
Revised Date: 1 March 2024

Explanatory Notes:

Stability data assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to the classification outlined in USP 797.[170,171]
***Vial stability*:** Stability of solution after first puncture or reconstituted solution.
Storage temperature: If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred (ie, to minimize growth of micro-organisms).
***Discard unused portion*:** Unused portion from single use vials should be discarded at the end of the day.
"overfill known" is stated if the manufacturer states overfill that is present is within acceptable limits.
"Complete administration within __" is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following preparation, usually including entire time required for preparation (from first puncture), storage, and administration of infusion.
Nomenclature for ***In-line filters*** has been standardized to 0.2 micron filter size. For more information, refer to CDM monograph.

Abbreviations:

BWI = bacteriostatic water for injection
CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor)
CSTD = closed system transfer device
D5W = dextrose 5% in water
DMA = N,N dimethylacetamide
F = refrigerate
Non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP)
NS = normal saline
PFL = protect from light
RT = room temperature
SAP **=** drug is approved for use through the Health Canada Special Access Program
SWI = sterile water for injection

References:

1. Generic Medical Partners Inc. Leucovorin calcium injection product monograph. Toronto, Ontario; 6 March 2020
2. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; December 5 2018
3. Pfizer Canada Inc. Leucovorin calcium injection product monograph. Kirkland, Quebec; 21 June 2018
4. Teva Canada Limited. Leucovorin calcium injection® product monograph. Toronto, Ontario; 5 May 2014
5. Hospira Healthcare Corporation. LEUCOVORIN CALCIUM INJECTION® product monograph. Saint-Laurent, Quebec; 7 June . 2007
6. Novopharm Limited (Teva). LEUCOVORIN CALCIUM® Injection product information package. Toronto, Ontario; undated undated
7. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 January 2006
8. Jenny Yeung. Medical Information Specialist, Teva Canada. Personal communication. 12 April2017

9. Jazz Pharmaceuticals Canada Incorporated. ZEPZELCA® product monograph. Mississauga, Ontario; September 29, 2021
10. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; May 1 2022
11. Linda Ewing.BD US Market Manager. WW Infusion Disposables. Personal communication. Feb2018
12. Pharma Mar. Lurbinectedin Compassionate Use: Preparation Guide for Infusion - edition 1. Madrid, Spain; April 2019
13. Marcan Pharmaceuticals Inc. Melphalan for injection product monograph. Ottawa, ON; July 26, 2019
14. Taro Pharmaceuticals Inc. Taro-Melphalan product monograph. Brampton, Ontario; April 5, 2019
15. Baxter Corporation. UROMITEXAN® product monograph. Mississauga, Ontario; 6 August 2013
16. Mona Ghobros BPharm MSc. Medical Information, Baxter Corporation. Personal communication. 29 November2018
17. Trissel's® 2 Clinical Pharmaceutics Database (database on the Internet). Mesna. Lexi-Comp Inc.; created by Lawrence A. Trissel, Available at: http://online.lexi.com. Accessed 29 November, 2018
18. Fresenius Kabi Canada Ltd. Mesna for injection product monograph. Richmond Hill, Ontario; 21 December 2017
19. BC Cancer. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; 19 September 2007
20. Fresenius Kabi Canada Ltd. Mesna for injection product monograph. Richmond Hill, Ontario; 30 March 2015
21. Accord Healthcare Inc. Methotrexate injection product monograph. Kirkland, Québec; October 30, 2019
22. Maia M, Farah ME, Belfort RN, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol 2007;91(9):1122-1124
23. Mayne Pharma Canada. Methotrexate Product Monograph. Montreal, Quebec; December 2003
24. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver, British Columbia: BC Cancer; September 1 2021
25. BC Cancer Lymphoma Tumour Group. (LYIT) BC Cancer Protocol Summary for Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine. Vancouver, British Columbia: BC Cancer; April 1 2022
26. Hematology/Oncology Pharmacy Association. HOPA News Clinical Pearls: Intrathecal Chemotherapy: Focus on Drugs, Dosing, and Preparation. 13(4) ed. Chicago, Illinois, USA: Hematology/Oncology Pharmacy Association; 2016
27. BC Cancer. Systemic Therapy Policy and Procedure III-50: Administration of High Alert Medications by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir. Vancouver, British Columbia; May 1 2019
28. Pfizer Canada-ULC. Methotrexate injection product monograph. Kirkland, Québec; July 8, 2019
29. Accord Healthcare Inc. Mitomycin product monograph. Kirkland, Quebec; 7 June 2017
30. Accord Healthcare Inc. Mitomycin product monograph. Kirkland, Quebec; 16 July 2018
31. Au JLS, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93(8):597-604
32. Jessie LS Au PharmD PhD. Professor, Ohio State University. Personal communication. 14 May2007
33. Myers AL, Zhang Y, Kawedia JD, et al. Solubilization and stability of mitomycin C solutions prepared for intravesical administration. Drugs R D 2017;17:297-304
34. Beijnen JH, Van Gijn R, Underberg WJM. Chemical stability of the antitumor drug mitomycin C in solutions for intravesical instillation. Journal of Parenteral Science and Technology 1990;44(6):332-335
35. Teva Canada Limited. Mitomycin for injection® product monograph. Toronto, Ontario; 30 June 2017
36. Fresenius Kabi Canada Ltd. Mitoxantrone injection® product monograph. Richmond Hill, Ontario; 28 September . 2016
37. Pfizer Canada Inc. Mitoxantrone injection product monograph. Kirkland, Quebec; 17 October 2018
38. Kyowa Kirin. POTELIGEO® product monograph. Oakville, Ontario; July 12, 2023
39. Kyowa Kirin Inc. POTELIGEO® full prescribing information. Bedminster, NJ; July 2021
40. Bristol-Myers Squibb Canada Co. OPDIVO® product monograph. Montreal, Canada; February 28, 2022
41. Hoffmann-La Roche Ltd. GAZYVA® product monograph. Mississauga, Ontario; 21 December . 2015
42. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007
43. Anna Sivojelezova MSc. Drug Information Associate, Hoffmann-La Roche Ltd. Personal communication. 24 April2015
44. Omega Laboratories Limited. OCTREOTIDE ACETATE solution product monograph. Montreal, Quebec; January 25, 2022
45. Novartis Pharmaceuticals Canada Inc. SANDOSTATIN® and SANDOSTATIN® LAR® product monograph. Dorval, Quebec; April 19 2021
46. Teva Canada Limited. OCTREOTIDE for injectable suspension Product Monograph. Toronto, Ontario; Aug 30, 2021
47. Dr. Reddy's Laboratories Canada Inc. Oxaliplatin injection product monograph. Mississauga, Ontario; February 8, 2022
48. Pfizer Canada Inc. Oxaliplatin injection product monograph. Kirkland, Quebec; 31 May 2017

49. Medical Information Pfizer Canada Inc. Personal communication. 6 June2017
50. Sandoz Canada Inc. Oxaliplatin injection product monograph. Boucherville, Quebec; 12 August 2015
51. Katryn Vosburg. Drug Information & Pharmacovigilance Specialist, Sandoz Canada Inc. Personal communication. 26 February2016
52. Teva Canada Limited. Teva-Oxaliplatin injection® product monograph. Toronto, Ontario; 11 September 2015
53. Accord Healthcare Inc. Paclitaxel Injection. Kirkland, Quebec; September 14, 2020
54. Mercure C. Stability of 0.1 mg/mL of paclitaxel for injection in sodium chloride (0.9%) solution. St Catharines, Ontario: Biolyse Pharma; 2 February 2007
55. Biolyse. PACLITAXEL FOR INJECTION® product monograph. St. Catherines, Ontario; 12 September 2013
56. Claude Mercure. Manager, Biolyse Pharma Corporation. Personal communication. 24 June2014
57. Zeng Z, Lazakovitch E. Study IR 120: Physical and Chemical Stability Study of Paclitaxel for Injection in 0.9 % Sodium Chloride in concentration range 0.012-0.12 mg/mL. Biolyse Pharma 2010
58. Biolyse. PACLITAXEL FOR INJECTION® product monograph. St. Catherines, Ontario; 2 December . 2005
59. Xu Q, Trissel LA, Martinez JF. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. Am J Hosp Pharm 1994;51(24):3058-60
60. Lisa Tavano. Biolyse Pharma Corporation. Personal communication. 14 May2012
61. Sandoz Canada Inc. Paclitaxel injection USP product monograph . Boucherville, Quebec; October 18, 2021
62. Celgene Inc. ABRAXANE® product monograph. Mississauga, Ontario; 31 August 2018
63. Aisling Cahill. Drug Safety and Medical Information Specialist. Celgene Inc. Personal communication. April 23,2015
64. Celgene Europe Limited. ABRAXANE® product monograph. Uxbridge, UK; 11 January 2013
65. Panacea Biotec Pharma Limited (distributed by Apotex Inc.). Nanoparticle, albumin-bound paclitaxel product monograph. Toronto, Ontario; November 16, 2021
66. Panacea Biotec Pharma Limited (R&D, LALRU). In-use infusion stability study report for paclitaxel powder for injectable suspension nanoparticle, albumin-bound paclitaxel (100 mg paclitaxel/vial). Toronto, Ontario; October 4, 2023
67. Pharmaceutical Partners of Canada. Pamidronate Disodium For Injection product monograph. Richmond Hill, Ontario; 18 January . 2010
68. Mayne Pharma (Canada) Inc. Pamidronate Package Insert. Montreal, Quebec; 2002
69. Omega Laboratories Ltd. Pamidronate Disodium product monograph. Montreal, Quebec; 06 June . 2005
70. Pfizer Canada-ULC. Pamidronate disodium for injection product monograph. Kirkland, Quebec; December 11, 2018
71. Sandoz Canada Inc. Pamidronate injection product monograph. Boucherville, Quebec; 28 February 2006
72. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007
73. Amgen Canada. VECTIBIX® product monograph. Mississauga, Ontario; 31 March 2017
74. Amgen Inc. VECTIBIX® full prescribing information. Thousand Oaks, California USA; June 2017
75. Amgen Canada. VECTIBIX® product monograph. Mississauga, Ontario; 5 March . 2009
76. Diane Lord. Medical Information Department, Amgen Canada Inc. Personal communication. 19 June2009
77. Servier Canada Inc. ONCASPAR® product monograph. Laval, Quebec; November 22 2021
78. Merck Canada Inc. KEYTRUDA® product monograph. Kirkland, Quebec; 6 December 2019
79. Accord Healthcare Inc. Pemetrexed disodium for injection product monograph. Kirkland, Quebec; 12 March 2015
80. Accord Healthcare Inc. Pemetrexed solution for injection product monograph. Kirkland, QC; April 26, 2021
81. Dr. Reddy's Laboratories Limited. Pemetrexed for Injection product monograph . Oakville, Ontario; April 12, 2017
82. Dr. Reddy's Laboratories Ltd. Pemetrexed for Injection product monograph. Mississauga, Ontario; May 3, 2022
83. Dr. Reddy's Laboratories Inc. Pemetrexed for injection full prescribing information (package insert). Princeton, NJ, USA; Mar 2022
84. Md Aslam. Medical information Associate. Drug information. Dr Reddy's Laboratories. Personal Communication (verbal). December 1,2022
85. Eli Lilly and Company. ALIMTA® product monograph. Indianapolis, Indiana, USA; September 2013
86. Taro Pharmaceuticals Inc. Pemetrexed disodium for injection product monograph. Brampton, Ontario; 30 August 2018
87. Hospira Inc. NIPENT® full prescribing information. Lake Forest, Illinois USA; Oct 2019
88. Hoffmann-La Roche Limited. PERJETA® product monograph. Mississauga, Ontario; April 12, 2013
89. Hoffmann-La Roche Limited. PHESGO® product monograph. Mississauga, Ontario; January 5, 2022
90. sanofi-aventis Canada Inc. MOZOBIL® product monograph. Laval, Quebec; 8 October . 2014
91. Maureen Coughlin BSc Pharm. Solutions in Health Inc. (acting as an authorized agent of sanofi-aventis and). Personal communication. 24 May2017
92. Hoffman-La Roche Limited. POLIVY® product monograph. Mississauga, Ontario; April 27, 2021

93. Servier Canada Inc. FOLOTYN® product monograph. Laval, Quebec; 19 October 2018
94. Marjolaine Migeon PharmD. Servier Canada Medical Information. Personal communication. 24 September2019
95. Pfizer Canada Inc. TOMUDEX® product monograph. Kirkland, Quebec; 8 August 2017
96. Eli Lilly Canada Inc. CYRAMZA® product monograph. Toronto, Ontario; 16 July 2015
97. Marilyn Bain BScN. Senior Medical Information Associate, Eli Lilly Canada Inc. Personal communication. 16 January2017
98. Hoffmann-La Roche Ltd. RITUXAN® product monograph. Mississauga, Ontario; October 10 2019
99. Hoffmann-La Roche Ltd. RITUXAN® SC product monograph. Mississauga, Ontario; March 21 2018
100. Sandoz Canada Inc. RIXIMYO® product monograph. Boucherville, Quebec; April 28 2020
101. Pfizer Canada-ULC. RUXIENCE® product monograph. Kirkland, Quebec; May 4 2020
102. Teva Canada Limited for Celltrion Healthcare Co Ltd. TRUXIMA® product monograph. Toronto, Ontario; July 22 2019
103. Celgene Inc. ISTODAX® product monograph. Mississauga, Ontario; 13 December 2016
104. Celgene Inc. INFO Rx ISTODAX® (romidepsin) for Injection. Mississauga, Ontario; 10 July 2017
105. Aisling Cahill. Drug Safety and Medical Information Specialist. Celgene Inc. Personal communication. 17 July2015
106. Gilead Sciences Canada Inc. TRODELVY® product monograph. Mississauga, ON; August 2, 2022
107. Gilead Medical Information. Gilead Sciences Inc. Personal Communication: Trodelvy® (sacituzumab govitecan) Concentration After Reconstitution. Jan 24,2022
108. Janssen Inc. SYLVANT® product monograph. Toronto, Ontario; 6 January 2016
109. Aadi Bioscience Inc. Pharmacy Manual Protocol PEX-002 (Version 4.0) Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Perivascular Epithelioid Cell Tumors (PEComa) or Patients with Relevant Genetic Mutations for mTOR Pathway Activation. Pacific Palisades, CA, USA; July 16, 2021
110. Aadi Bioscience Inc. ABI-009 sirolimus albumin-bound nanoparticle (packaging information - BOX). Pacific Palisades, CA; Feb 1 , 2022
111. Aadi Bioscience Inc. ABI-009 sirolimus albumin-bound nanoparticle (packaging information - VIAL). Pacific Palisades, CA; Feb 1, 2022
112. Aadi Bioscience Inc. ABI-009 (*nab*-Sirolimus) Investigator's Brochure - version 10.0. Pacific Palisades, CA, USA; July 27, 2021
113. Keocyt. Streptozocin Keocyt summary of product characteristics, version 5. Montrouge, France; February 2016
114. Keocyt. ZANOSAR® package leaflet. Montrouge, France; 24 February 2016
115. Keocyt. ZANOSAR® summary of product characteristics, version 3. Montrouge, France; 31 October 2017
116. Keocyt-Riemser Pharma. Marie-Laure Vedel, Sales Order Handling and Hospital Relationship Manager. 16 September2021
117. Medison Pharma Canada Inc.for Immunocore Ireland Limited. KIMMTRAK® product monograph. Toronto, Ontario; June 7, 2022
118. Pfeiffer, Connie. Head of Medical Affairs Immunocore. Personal Communication. Feb 16,2022
119. Immunocore and Clinigen. MAP Pharmacy Manual – Tebentafusp 0.2 mg/mL formulation. Abingdon, Oxfordshire, UK; May 19, 2021
120. Immunocore Commercial-LLC. KIMMTRAK® full prescribing information. Conshohocken, PA, USA; Jan 2022
121. Janssen Inc. TECVAYLI® product monograph. Toronto, Ontario; July 26, 2023
122. Janssen Research & Development LLC. Investigational product preparation and Administration instructions for subcutaneous Administration of 10 mg/mL and 90 mg/mL Teclistamab (JNJ-64007957) For Weight-Based Dosing in mcg/kg for Managed Access Programs - Version 6.0 . Beerse, Belgium; June 9 2023
123. de Lemos, M. BC Cancer Provincial Pharmacy Professional Practice Leader and Drug Information Coordinator. SBAR: Teclistamab Subcutaneous Injection for Multiple Myeloma at BC Cancer. (draft). BC Cancer - Systemic Therapy Program 2023
124. Pfizer Canada Inc (for Wyeth Canada). TORISEL® product monograph. Kirkland, Quebec; 21 December . 2016
125. Anna Sivojelezova M.Sc. Medical Information Associate, Wyeth. Personal communication. 6 January2010
126. Bristol-Myers Squibb Canada. VUMON® product monograph. St. Laurent, Quebec; 26 October . 2004
127. Trissel's®2 IV Compatibility (database on the Internet). Teniposide. Thomson Reuters MICROMEDEX® 2.0, updated periodically. Available at: http://www.micromedex.com. Accessed 27 April, 2011
128. Adienne-SA. TEPADINA® product monograph. Lugano, Switzerland; 28 March 2017
129. AHFS Drug Information® (database on the Internet). Thiotepa. Lexi-Comp Inc., 2018. Available at: http://online.lexi.com. Accessed 21 August, 2018
130. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver, British Columbia: BC Cancer; 1 October 2018
131. Sanofi Genzyme. THYROGEN® product monograph. Mississauga, Ontario; July 29, 2021
132. Lillian Phan. Senior Manager, Medical Affairs US, EU & New Markets. Personal communication. 15 January2021

133. BeiGene Ltd. Clinical Study Pharmacy Manual Protocol BGB-A317-207: An phase 2, open-label study of BGB-A317 in patients with relapsed or refractory mature T- and NK-cell neoplasms. (Version 5.0). San Mateo, California, USA; 8 November 2019
134. BeiGene Ltd. Tislelizumab (BGB-A317) Product Information for Investigator Sponsored Research (ISR) Investigators (Version 0.0). San Mateo, California, USA; 19 May 2020
135. Hoffmann-La Roche Limited. ACTEMRA® product monograph. Mississauga, Ontario; 27 October 2017
136. Accord Healthcare Inc. Topotecan hydrochloride for injection product monograph. Kirkland, Quebec; 9 May 2019
137. Pfizer Canada Inc. Topotecan hydrochloride for injection product monograph. Kirkland, Quebec; 5 January 2018
138. Sandoz Canada Inc. Topotecan injection product monograph. Boucherville, Quebec; 5 September . 2014
139. Hoffmann-La Roche Limited. HERCEPTIN® product monograph. Mississauga, Ontario; May 7, 2020
140. Celltrion Healthcare Co Ltd (distributed by Teva Canada Limited). HERZUMA® product monograph. Toronto, Ontario; 20 October 2020
141. BGP Pharmacy ULC. OGIVRI® product monograph. Etobicoke, Ontario; 3 May 2019
142. ULC Pfizer Canada. TRAZIMERA® product monograph. Kirkland, Quebec; 15 August 2019
143. AstraZeneca Canada Inc. ENHERTU® product monograph. Mississauga, Ontario; 15 April 2021
144. AstraZeneca Canada Inc. Medical Information. 5 October2021
145. Hoffmann-La Roche Limited. KADCYLA® product monograph. Mississauga, Ontario; 11 September 2013
146. Hoffmann-La Roche Limited. KADCYLA® product monograph. Mississauga, Ontario; July 3, 2020
147. Medexus Inc. TRECONDYV® product monograph. Bolton, Ontario; June 25, 2021
148. Erin Wallace. Ontario Territory Manager, Medexus Pharmaceuticals Inc. Personal Communication - TRECONDYV®. November 2,2021
149. Medical Information team. Medexus Pharmaceuticals Inc. Personal Communication - TRECONDYV®. November 1,2021
150. medac GmbH. TRECONDI® summary of product characteristics. Wedel, Germany;
151. medac-UK. TREOSULFAN injection® summary of product characteristics. Wedel, Germany; 26 Jan 2017
152. medac-UK. TREOSULFAN injection® Details about Handling and Stability. Hamburg, Germany; August 2008
153. Henrik Fenger. Management Associate, International Division medac. Personal communication. 03 March2010
154. medac-UK. TREOSULFAN injection® summary of product characteristics. Hamburg, Germany; 24 Jun 2008
155. ULC Pfizer Canada. Vinblastine sulfate injection product monograph. Kirkland, Quebec; 18 April 2019
156. Lexi-Drugs® (database on the Internet). VinBLAStine. Lexi-Comp Inc., 2020. Available at: http://online.lexi.com. Accessed 30 January, 2020
157. BC Cancer Provincial Systemic Therapy Program. Policy V-40: Dispensing and Labelling of Vinca Alkaloid Preparations. Vancouver, British Columbia: BC Cancer; 1 April 2015
158. World Health Organization. Information Exchange System - Vincristine (and other vinca alkaloids) should only be given intravenously via a minibag. Alert No. 115 ed. Geneva, Switzerland: World Health Organization; 18 July 2007
159. Teva Canada Limited. Vinblastine sulfate injection product monograph. Toronto, Ontario; 22 October 2019
160. Pfizer Canada-ULC. Vincristine sulfate injection product monograph. Kirkland, Québec; July 26, 2021
161. Teva Canada Limited. Vincristine sulfate injection® product monograph. Scarborough, Ontario; March 27, 2014
162. Pharmaceutical Partners of Canada. Vinorelbine Injection product monograph. Richmond Hill, Ontario; 15 January . 2008
163. Generic Medical Partners Inc. Vinorelbine Injection product monograph. Toronto, Ontario; 3 September 2014
164. Teva Canada Limited. Vinorelbine tartrate for Injection product monograph. Toronto, Ontario; 20 March 2014
165. Innomar Strategies Inc. (for Dr. Reddy's Laboratories Limited). Zoledronic acid for injection concentrate® product monograph. Oakville, Ontario; 11 March 2015
166. Marcan Pharmaceuticals Inc. Zoledronic acid concentrate for injection product monograph. Ottawa, Ontario; 5 February 2018
167. MDA Inc. Zoledronic acid for injection product monograph. Mississauga, Ontario; 11 August 2015
168. Novartis Pharmaceuticals Canada Inc. ZOMETA® product monograph. Dorval, Quebec; 26 July 2013
169. Sandoz Canada Inc. Zoledronic Acid - Z® product monograph. Boucherville, Quebec; 02 December 2016
170. The United States Pharmacopeia, (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2004
171. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5